Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Ciena Fiscal Q1 2026 Earnings Call - Record demand lifts revenue and backlog to $7B, supply to constrain fulfillment into 2027
Ciena reported a blowout fiscal Q1 2026, with record revenue of $1.43 billion, adjusted gross margin of 44.7%, and adjusted EPS of $1.35. Orders were “incredibly strong,” lifting backlog by about $2 b...
- Revenue hit a record $1.43 billion in fiscal Q1 2026, at the top end of guidance, up 33% year-over-year.
- Adjusted gross margin came in at 44.7% for the quarter, ahead of expectations and approaching management’s 45% milestone.
- Adjusted EPS was $1.35, more than double Q1 a year ago, with adjusted net income of $197 million.
- +16 more takeaways
ImmuCell Corporation Q4 2025 Earnings Call - Pivot to First Defense and manufacturing scale lifts margins despite Re-Tain write-downs
ImmuCell closed 2025 with $27.6 million in product sales, a modest full year revenue gain of 4.3% and a clear strategic reset. Management pivoted decisively to the First Defense franchise, resolved a ...
- Company pivoted to focus exclusively on the First Defense franchise and paused investment in the Re-Tain subclinical mastitis program in December 2025.
- Full year product sales were $27.6 million in 2025, up 4.3% versus 2024; Q4 product sales were $7.6 million, down 1.6% year-over-year.
- Domestic Q4 sales rose 8.7% year-over-year to about $7.0 million; international Q4 sales fell to roughly $600,000, about 8% of Q4 sales, primarily due to Canadian order timing.
- +12 more takeaways
Altimmune Q4 2025 Earnings Call - Pemvidutide set for FDA-aligned global 1,800-patient Phase 3 after strong 48-week MASH data
Altimmune entered 2026 with a new CEO and a tight focus on advancing pemvidutide, its dual glucagon/GLP-1 liver-directed candidate. Management reported 48-week Phase 2 MASH data showing early MASH res...
- New CEO Jerry Durso joined in January and is prioritizing pemvidutide as a late-stage, liver-focused program.
- Pemvidutide received FDA Breakthrough Therapy designation in MASH, recognizing preliminary evidence of substantial improvement over available therapies.
- Phase 2 IMPACT data: pemvidutide showed early MASH resolution at 24 weeks and clear anti-fibrotic signals at 48 weeks, with non-invasive tests such as ELF and liver stiffness improving, especially at 1.8 mg.
- +11 more takeaways
Stratasys Q4 2025 Earnings Call - Manufacturing and Aerospace Momentum, but FX and Tariffs Dent Margins
Stratasys closed 2025 showing the strategy is working, even if the macro backdrop is not. The company increased the share of revenue from manufacturing to 37.5% as it converts aerospace, defense, auto...
- Q4 2025 revenue was $140.0 million, down 6.9% year over year; full year revenue was $561.1 million versus $572.5 million in 2024.
- Adjusted EBITDA for Q4 was $9.2 million, a 6.6% EBITDA margin, down from $14.5 million and 9.6% in Q4 2024; full year adjusted EBITDA was $28.5 million, 5.2% of revenue.
- Non-GAAP net income for Q4 was $6.2 million or $0.07 per diluted share; full year non-GAAP net income was $12.7 million or $0.15 per diluted share.
- +12 more takeaways
BJ’s Wholesale Club Fourth Quarter Fiscal 2025 Earnings Call - Membership Surge, Club Buildout and Digital Lift Offset Margin Pressure
BJ’s closed fiscal 2025 with clear momentum, growing members, opening more clubs than ever, and pushing digital penetration higher, all while delivering record full-year EPS. The company added over 50...
- Membership momentum is the headline, with over 500,000 net new members in FY25, total membership topping 8 million, and a rare 90% tenured renewal rate for the fourth consecutive year.
- Management reported record full-year Adjusted EPS of $4.40, and Q4 Adjusted EPS of $0.96, up 3.2% year-over-year, hitting the high end of revised guidance for the year.
- Net sales for Q4 were approximately $5.4 billion, up 5.5% year-over-year; merchandise comparable club sales excluding gasoline rose 2.6% in Q4.
- +12 more takeaways
Lexicon Pharmaceuticals Q4 and Full Year 2025 Earnings Call - Zynquista Resubmission Planned, Multiple Clinical Catalysts in 2026
Lexicon enters 2026 with a clear, catalyst-heavy playbook: a planned NDA resubmission for Zynquista in type 1 diabetes contingent on Steno-1 exposure and DKA safety data, an on-track SONATA-HCM Phase ...
- Company summary: Lexicon is focused on three late-stage assets, sotagliflozin (cardiometabolic, HCM and T1D), pilavapadin (chronic neuropathic pain, Phase 3-ready), and LX9851 (oral obesity program now with Novo Nordisk).
- Zynquista (sotagliflozin in T1D): FDA indicated that Steno-1 investigator-initiated study data may support an NDA resubmission if prespecified patient exposure and DKA safety criteria are met, and Lexicon expects to resubmit in 2026 with a potential approval before year-end.
- Regulatory bar for DKA safety: FDA communicated a target DKA rate comparable to the inTANDEM 400 mg arm, roughly 3.5 cases per 100 patient-years, and Lexicon says current Steno-1 exposure and DKA tracking give them high confidence for submission plans.
- +12 more takeaways
Bioventus Q4 2025 Earnings Call - Scaling PNS, PRP and Ultrasonics Investments to Accelerate Growth While Preserving ~20% EBITDA
Bioventus closed 2025 with a tidy quarter and a clear playbook: tighten the core, harvest cash, then spend aggressively on new growth engines. Q4 revenue was $158 million, up 3% year-over-year and +10...
- Q4 headline, revenue $158 million, +3% year-over-year, organic growth +10% after adjusting for the Advanced Rehabilitation divestiture.
- Adjusted EBITDA $37 million in Q4, up $8 million versus prior year, representing a 30% increase and a 23% Adjusted EBITDA margin, up ~490 basis points year-over-year.
- Quarterly cash from operations reached a record ~$38 million, full-year cash from operations nearly $75 million, a ~92% increase over 2024.
- +12 more takeaways
Liquidia Corporation Full Year 2025 Earnings Call - YUTREPIA launch reached profitability and targets $1B franchise by 2027
Liquidia says its YUTREPIA launch moved from proof to profit faster than most imagined. The company reported $148.3 million in 2025 net product sales, including $90.1 million in Q4, and posted two con...
- YUTREPIA generated $148.3 million in net product sales for full year 2025, including $90.1 million in Q4.
- Q4 marked Liquidia’s second consecutive quarter of improving profitability, with non-GAAP adjusted EBITDA of $27.3 million and net income of $14.6 million.
- The company ended 2025 with $190.7 million in cash and equivalents and produced $33 million of positive cash flow in Q4, calling the business a cash-generating growth engine.
- +11 more takeaways
Seaport Entertainment Group Q4 2025 Earnings Call - 250 Water Street sale closes, ~$75M cash and Tin Building reposition to Balloon Museum to boost EBITDA
Seaport finished 2025 with a clearer runway. The company closed the long-anticipated sale of 250 Water Street in early February, unlocking roughly $75 million net proceeds and eliminating about $7 mil...
- Sale of 250 Water Street closed in early February, generating approximately $75 million net proceeds after post-closing obligations, with most of those obligations expected resolved by Q3 2026.
- Sale eliminates about $7 million of annual cash burn related to interest and carrying costs tied to 250 Water Street.
- Tin Building culinary concept with Jean-Georges closed; new 5-year initial lease with Lux Entertainment will host the Balloon Museum, with tenant fit-out at their expense and company landlord work estimated at about $5 million.
- +16 more takeaways
REGENXBIO Q4 2025 Earnings Call - RGX-202 nears pivotal readout and an accelerated approval push for Duchenne
REGENXBIO closed 2025 with a tightly focused slate of late-stage catalysts and a familiar regulatory hangover. The big headline is RGX-202 for Duchenne: pivotal dosing completed, robust phase I/II fun...
- RGX-202 (Duchenne) pivotal enrollment completed in October 2025, with top-line pivotal data expected early in Q2 2026.
- REGENXBIO plans a pre-BLA meeting with FDA mid-2026 and intends to pursue accelerated approval, supporting microdystrophin with substantial functional data.
- Phase I/II RGX-202 data show durable functional differentiation, including an average +7.4 NSAA improvement versus the CTAP model at 18 months; company stresses strong results in older patients where decline is expected.
- +12 more takeaways